SCD Stock Overview
Engages in the production and marketing of preparations and medicines for human use in Romania and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for SCD from our risk checks.
Zentiva S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | RON 4.52 |
| 52 Week High | RON 4.60 |
| 52 Week Low | RON 2.72 |
| Beta | 0.36 |
| 11 Month Change | 14.72% |
| 3 Month Change | 1.35% |
| 1 Year Change | 61.43% |
| 33 Year Change | 72.52% |
| 5 Year Change | 36.97% |
| Change since IPO | 9,000.06% |
Recent News & Updates
Recent updates
Take Care Before Diving Into The Deep End On Zentiva S.A. (BVB:SCD)
Jul 30
Zentiva S.A. (BVB:SCD) Doing What It Can To Lift Shares
Mar 02Zentiva's (BVB:SCD) Solid Earnings May Rest On Weak Foundations
May 24Zentiva (BVB:SCD) Has Gifted Shareholders With A Fantastic 201% Total Return On Their Investment
Mar 01Zentiva S.A.'s (BVB:SCD) Stock Is Going Strong: Have Financials A Role To Play?
Jan 25
Zentiva S.A. (BVB:SCD) Investors Are Less Pessimistic Than Expected
Dec 18Shareholder Returns
| SCD | RO Pharmaceuticals | RO Market | |
|---|---|---|---|
| 7D | 14.7% | -3.0% | -2.4% |
| 1Y | 61.4% | 4.3% | 11.1% |
Return vs Industry: SCD exceeded the RO Pharmaceuticals industry which returned 3.6% over the past year.
Return vs Market: SCD exceeded the RO Market which returned 11.1% over the past year.
Price Volatility
| SCD volatility | |
|---|---|
| SCD Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in RO Market | 10.1% |
| 10% least volatile stocks in RO Market | 2.2% |
Stable Share Price: SCD has not had significant price volatility in the past 3 months compared to the RO market.
Volatility Over Time: SCD's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1962 | 1,035 | Simona Cocos | www.zentiva.ro |
Zentiva S.A. engages in the production and marketing of preparations and medicines for human use in Romania and internationally. The company develops pharmaceutical products in various therapeutic areas, such as cardiovascular diseases, anti-inflammatory and pain-relieving medications, urologists, blood diseases, gastrointestinal and metabolic disorders, central nervous system, infections, respiratory systems, and other. It also offers educational materials for healthcare professionals and patients.
Zentiva S.A. Fundamentals Summary
| SCD fundamental statistics | |
|---|---|
| Market cap | RON 3.15b |
| Earnings (TTM) | RON 270.78m |
| Revenue (TTM) | RON 1.09b |
11.6x
P/E Ratio2.9x
P/S RatioIs SCD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SCD income statement (TTM) | |
|---|---|
| Revenue | RON 1.09b |
| Cost of Revenue | RON 449.28m |
| Gross Profit | RON 644.81m |
| Other Expenses | RON 374.03m |
| Earnings | RON 270.78m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.39 |
| Gross Margin | 58.94% |
| Net Profit Margin | 24.75% |
| Debt/Equity Ratio | 0% |
How did SCD perform over the long term?
See historical performance and comparison